bioMerieux (OTCMKTS:BMXMF) Shares Gap Up – What’s Next?

bioMerieux (OTCMKTS:BMXMF)’s stock price gapped up prior to trading on Tuesday . The stock had previously closed at $77.93, but opened at $82.78. bioMerieux shares last traded at $82.78, with a volume of 259 shares changing hands.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of bioMerieux in a research report on Wednesday, June 17th. Zacks Research upgraded shares of bioMerieux to a “hold” rating in a research note on Tuesday, April 28th. Morgan Stanley cut shares of bioMerieux from an “overweight” rating to an “underweight” rating in a report on Tuesday, June 23rd. UBS Group downgraded shares of bioMerieux from a “buy” rating to a “neutral” rating in a research report on Monday, June 1st. Finally, Piper Sandler initiated coverage on bioMerieux in a report on Thursday, June 11th. They issued a “neutral” rating on the stock. Five equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, bioMerieux has an average rating of “Reduce”.

bioMerieux Stock Performance

The business has a fifty day moving average of $82.43 and a two-hundred day moving average of $104.16. The company has a quick ratio of 1.48, a current ratio of 2.39 and a debt-to-equity ratio of 0.08.

bioMerieux Company Profile

bioMérieux is a global leader in in vitro diagnostics, specializing in the development, manufacture and distribution of diagnostic solutions that determine the source of disease and contamination to improve patient health and ensure consumer safety. The company’s product portfolio encompasses a broad range of assays and instruments for microbiological and immunoassay testing, including molecular diagnostics for infectious diseases, immunoassays for autoimmune and oncology markers, and traditional microbial identification and antimicrobial susceptibility testing.